Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 8.3%

DiaMedica Therapeutics Inc. (NASDAQ:DMACGet Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 212,600 shares, a growth of 8.3% from the February 29th total of 196,300 shares. Based on an average trading volume of 42,900 shares, the short-interest ratio is presently 5.0 days.

Analysts Set New Price Targets

DMAC has been the topic of several analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $6.00 price objective (down from $7.00) on shares of DiaMedica Therapeutics in a research report on Thursday, March 21st. Craig Hallum dropped their price objective on DiaMedica Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 21st.

Get Our Latest Stock Analysis on DMAC

DiaMedica Therapeutics Stock Performance

Shares of DMAC traded down $0.02 during mid-day trading on Wednesday, hitting $2.71. 2,499 shares of the company traded hands, compared to its average volume of 40,543. The stock has a market cap of $102.87 million, a price-to-earnings ratio of -4.40 and a beta of 1.69. The stock has a 50-day moving average price of $2.91 and a two-hundred day moving average price of $2.70. DiaMedica Therapeutics has a 1 year low of $1.48 and a 1 year high of $4.75.

DiaMedica Therapeutics (NASDAQ:DMACGet Free Report) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.14) EPS for the quarter, meeting analysts’ consensus estimates of ($0.14). On average, analysts forecast that DiaMedica Therapeutics will post -0.69 EPS for the current year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of hedge funds have recently modified their holdings of the business. Jane Street Group LLC boosted its position in shares of DiaMedica Therapeutics by 108.3% in the fourth quarter. Jane Street Group LLC now owns 20,840 shares of the company’s stock worth $33,000 after purchasing an additional 10,837 shares during the period. Avantax Advisory Services Inc. purchased a new stake in DiaMedica Therapeutics in the 4th quarter worth $36,000. BNP Paribas Arbitrage SNC boosted its stake in DiaMedica Therapeutics by 344.6% during the second quarter. BNP Paribas Arbitrage SNC now owns 9,800 shares of the company’s stock valued at $42,000 after buying an additional 7,596 shares during the last quarter. Citadel Advisors LLC grew its stake in shares of DiaMedica Therapeutics by 93.8% in the 3rd quarter. Citadel Advisors LLC now owns 34,912 shares of the company’s stock worth $43,000 after buying an additional 16,900 shares in the last quarter. Finally, Stonebridge Capital Advisors LLC purchased a new position in DiaMedica Therapeutics during the third quarter worth $52,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases.

Featured Articles

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.